Under a revenue share the platform charges a percentage of what patients pay, either instead of or on top of a monthly fee. Rates in white-label telehealth commonly run from the high teens to roughly half of patient revenue once processing and medication costs are accounted for.
The structural problem is that the fee is indexed to your success rather than to the cost of serving you. Software does not become more expensive to run because your ad account performed well, but a percentage fee behaves as though it does.
The effect compounds in the wrong direction over a patient's life. Month one is your expensive month, because you paid to acquire that patient. Month twelve is pure contribution. A percentage takes the same cut from both, and some schedules take a larger share as the patient matures.
On $300,000 of monthly billings, a 20% revenue share is $60,000 a month. A flat platform fee plus a transaction fee at processing cost is a small fraction of that, and does not increase when you win.
Revenue share, in practice
When the platform is genuinely funding your working capital, carrying medication and lab costs, absorbing merchant reserves and chargebacks, and running clinical operations end to end. That is a real transfer of risk. It stops being reasonable when the platform is only providing software.